Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-06-24 00:00:00 ET · period of report 2025-06-20 · accession 0000950170-25-089646 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-24 | 2025-06-20 | BBIO | Dachille Douglas A. | Dir | A - Grant | $0.00 | +6,589 | 6,589 | New | $0 |
| D | 2025-06-24 | 2025-06-20 | BBIO | Dachille Douglas A. | Dir | A - Grant | $0.00 | +8,425 | 8,425 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-20 | A | A | 6,589 | $0.00 | 6,589 | D | — | — | (F2) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-06-20 | A | A | 8,425 | $0.00 | 8,425 | D | $41.73 · — to 2035-06-19 | 8,425 Common Stock | (F4) One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. |